<DOC>
	<DOCNO>NCT00096915</DOCNO>
	<brief_summary>The propose study design test novel dosing paradigm would facilitate treatment anemia CKD patient dialysis . Anemic patient hemo peritoneal dialysis achieve maintained target hemoglobin ( Hb ) every week ( Q2W ) dose darbepoetin alfa dose interval extend monthly ( QM ) dosing .</brief_summary>
	<brief_title>Study Evaluating Darbepoetin Alfa Subjects With Chronic Kidney Disease ( CKD ) Receiving Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Diagnosis chronic kidney disease ( CKD ) receive dialysis &gt; 3 month enrollment Clinically stable , judgment investigator Mean Hb &gt; 11.0 g/dL ( 110 g/L ) &lt; 13.0 g/dL ( 130 g/L ) Transferrin saturation ( Tsat ) &gt; 19.5 % Serum vitamin B12 folate level low limit normal range Receiving stable Q2W IV SC dose Aranesp® ( darbepoetin alfa ) . A stable dose define less equal 25 % change dose 6week period immediately prior enrollment miss dos period Scheduled receive kidney transplant Diastolic blood pressure great 110 mm Hg systolic BP great 180 mm Hg screen Acute myocardial ischemia Hospitalization congestive heart failure , myocardial infarction , deep vein thrombosis , stroke transient ischemic attack within 12 week enrollment Parathyroid hormone ( PTH ) level great 1500 pg/mL ( 158.0 pmol/L ) Major surgery within 12 week enrollment ( exclude vascular access surgery ) Currently receive antibiotic therapy systemic infection Known positive HIV antibody positive hepatitis B surface antigen Clinical evidence current malignancy and/or receive systemic chemotherapy/radiotherapy exception basal cell squamous cell carcinoma skin cervical intraepithelial neoplasia Red blood cell ( RBC ) transfusion within 8 week enrollment Androgen therapy within 8 week enrollment Systemic hematologic disease ( e.g. , sickle cell anemia , myelodysplastic syndrome , hematologic malignancy , myeloma , hemolytic anemia ) Any disorder may impact ( judgment investigator ) ability give inform consent participation study Pregnant breastfeed woman All subject must practice adequate contraception ( judgment investigator ) throughout trial Treatment investigational agent device within 30 day enrollment schedule receive investigational agent specify protocol course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>chronic kidney disease , CKD</keyword>
	<keyword>renal failure</keyword>
	<keyword>anemia</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>peritoneal dialysis</keyword>
	<keyword>Aranesp® , Darbepoetin Alfa</keyword>
</DOC>